Nicox, an emerging French ophthalmic firm, has replaced some members of its Board of Directors. Adrienne Graves and Luzi von Bidder joined the Board last week, filling vacancies left by the departure of Vaughn Kailian and Vince Anido.
Kailian, who has been a member of the Board since 2001, told Nicox he was stepping down for personal reasons, while Anido, who joined the Board in June 2013, has left due to his increasing responsibilities at Aerie Pharmaceuticals, Inc.
New Board member Adrienne Graves is the former CEO of Santen Inc., the US subsidiary of Japanese ophthalmic powerhouse Santen, and Luzi von Bidder is the former Chairman of Acino Holding AG and former CEO of Novartis Ophthalmics AG.
At Nicox’s General Meeting this autumn the company will vote on the acquisition of Aciex Therapeutics and propose the appointment of Les Kaplan, Executive Chairman of Aciex, to Nicox’s Board.
Nicox’s main asset in ophthalmology is latanoprostene bunod, a compound based on the company’s proprietary platform based on nitric oxide. It is currently in Phase III clinical development in collaboration with Bausch + Lomb for the treatment of glaucoma and ocular hypertension.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...